Processing...
Clinical Trials for Kidney Cancer
Search
Search
There are 134 active trials for advanced/metastatic kidney cancer.
Click on a trial to see more information.
134 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Relapsed/refractory pediatric, adolescent, and young adult patients (≤30 years) with histologically confirmed solid tumors or CNS malignancies receive vincristine/irinotecan/temozolomide (VIT), with vorinostat added from cycle 2 onward in a dose-escalation schema. Vorinostat is an oral histone deacetylase (HDAC) inhibitor intended to enhance DNA-damaging chemotherapy sensitivity; trial defines its tolerated dose with VIT and assesses preliminary activity.
ClinicalTrials.gov ID: NCT04308330
TrialFetch AI summary: Enrolling adults with metastatic rare genitourinary cancers across multiple histologic cohorts (e.g., small cell/neuroendocrine bladder, variant urothelial, penile, sarcomatoid/unclassified RCC, collecting duct, renal medullary, urethral; including a bone-only GU cohort), with up to two prior lines allowed (cohort-specific exceptions. Patients receive cabozantinib (MET/VEGFR2/AXL multi-kinase inhibitor) plus nivolumab (PD-1) and ipilimumab (CTLA-4) for up to 2 years.
ClinicalTrials.gov ID: NCT03866382
TrialFetch AI summary: Adults with advanced or metastatic renal cell carcinoma, urothelial carcinoma, or castration-resistant prostate cancer receive oral DCC-2812 monotherapy, a first-in-human, selective GCN2 activator that engages the integrated stress response (eIF2α phosphorylation/ATF4) to disrupt tumor survival pathways. Dose-escalation evaluates safety, dose-limiting toxicities, and PK, with preliminary antitumor activity assessed.
ClinicalTrials.gov ID: NCT06966024
TrialFetch AI summary: Adults with advanced/metastatic solid tumors after standard therapy receive REGN10597, an intravenously delivered anti–PD-1–IL2RA–IL2 fusion protein designed to target IL-2 signaling to PD-1–positive activated T cells while limiting systemic IL-2 effects; expansion cohorts enroll melanoma and clear-cell RCC. Key exclusions include prior IL-2/IL-15/IL-7 therapy, recent checkpoint inhibitors or systemic therapy, active immune-related AEs, significant autoimmune disease, or need for systemic immunosuppression.
ClinicalTrials.gov ID: NCT06413680
TrialFetch AI summary: Adults with advanced/metastatic MUC1-overexpressing solid tumors: dose-escalation/expansion of M0324, an investigational MUC1-conditional CD40 agonist antibody, as monotherapy (post–standard therapy) or combined with pembrolizumab after prior ICI progression; separate cohort tests M0324 plus mFOLFIRINOX as first-line therapy for metastatic pancreatic ductal adenocarcinoma. Key exclusions include significant GI inflammation (e.g., chronic grade ≥2 diarrhea/IBD) and uncontrolled cardiovascular disease.
ClinicalTrials.gov ID: NCT07166601
TrialFetch AI summary: Enrolling adults with advanced/metastatic clear-cell or papillary renal cell carcinoma who are chronically hemodialysis-dependent (stable ≥3 months), ECOG 0–2, and have no suitable standard systemic therapy available/appropriate or have declined it (measurable disease required in the expansion cohort). Patients receive single-arm intravenous orellanine (ONC175), a synthetic mushroom-derived nephrotoxin being developed as a kidney-selective, organ-targeted RCC therapy that disrupts cellular metabolism/protein synthesis and induces tumor cell death, with dose escalation/expansion to define safety/MTD, PK, and preliminary efficacy.
ClinicalTrials.gov ID: NCT05287945
TrialFetch AI summary: Enrolling adults with locally advanced or metastatic clear cell RCC (ECOG 0–1) previously treated with standard systemic therapy—dose escalation requires ≥2 prior regimens including immunotherapy and a targeted therapy, and expansion cohorts require prior exposure to both a PD-1/L1 inhibitor and a VEGF TKI. Participants receive oral BMS-986506 monotherapy (first-in-human small molecule; target/mechanism not publicly specified) with primary focus on safety/DLTs and secondary pharmacokinetics and preliminary RECIST activity.
ClinicalTrials.gov ID: NCT07195682
TrialFetch AI summary: For adults with locally advanced or metastatic unresectable clear cell renal cell carcinoma who have progressed on or declined standard therapies (ECOG 0–1, RECIST-measurable disease, eGFR ≥60, with available FFPE tumor tissue), this single-arm study evaluates escalating oral NEO-811 monotherapy given in 21-day cycles. NEO-811 is an investigational agent with an undisclosed molecular target/mechanism, assessed primarily for safety/tolerability and dose selection with preliminary RECIST activity.
ClinicalTrials.gov ID: NCT07300241
TrialFetch AI summary: Enrolls children/AYA age >12 months to <30 years with recurrent/refractory non-CNS solid tumors (dose-finding/expansion, including an HRR-altered cohort) and randomizes patients with first-relapse, EWSR1-rearranged Ewing sarcoma to compare efficacy. Treatment is nanoliposomal irinotecan (Onivyde; topoisomerase I–mediated DNA damage) on days 1 and 8 of 21-day cycles combined with either talazoparib (PARP1/2 inhibitor with PARP-trapping) or temozolomide (oral DNA-alkylating agent).
ClinicalTrials.gov ID: NCT04901702
TrialFetch AI summary: Enrolling adults with ECOG 0–1 and advanced CD70-expressing malignancies needing additional therapy: ccRCC after ≥1 prior line including ICI+TKI, DLBCL/high-grade B-cell lymphoma after ≥2 prior lines including immunochemotherapy and salvage, peripheral T-cell lymphoma after ≥1 systemic therapy, or CTCL (mycosis fungoides/Sézary) stage IIB+ with B0/B1 blood involvement after ≥1 systemic therapy. Participants receive INCA036873 monotherapy, an investigational CD70×CD3 bispecific T-cell engager intended to redirect T cells to kill CD70-positive tumor cells.
ClinicalTrials.gov ID: NCT07195916